Biocryst Pharma Inc (BCRX)

Jan 10, 2025, 7:00 AM EST - 7 days ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

Jan 7, 2025, 7:00 AM EST - 10 days ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:00 AM EST - 11 days ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 9, 2024, 1:47 PM EST - 5 weeks ago

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

Nov 18, 2024, 2:00 AM EST - 2 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

Nov 6, 2024, 7:00 AM EST - 2 months ago

BioCryst to Present at Upcoming Investor Conferences

Nov 4, 2024, 11:00 AM EST - 2 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript

Oct 21, 2024, 7:00 AM EDT - 3 months ago

BioCryst to Report Third Quarter 2024 Financial Results on November 4

Oct 14, 2024, 7:00 AM EDT - 3 months ago

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

Oct 2, 2024, 7:00 AM EDT - 3 months ago

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

Sep 30, 2024, 7:00 AM EDT - 3 months ago

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

Sep 17, 2024, 7:00 AM EDT - 4 months ago

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

Sep 6, 2024, 2:00 AM EDT - 4 months ago

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

Aug 5, 2024, 11:44 AM EDT - 5 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 7:00 AM EDT - 5 months ago

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 22, 2024, 7:00 AM EDT - 6 months ago

BioCryst to Report Second Quarter 2024 Financial Results on August 5

Jul 21, 2024, 7:30 AM EDT - 6 months ago

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Jul 9, 2024, 7:00 AM EDT - 6 months ago

ORLADEYO® (berotralstat) Approved in Peru

Jun 2, 2024, 4:00 AM EDT - 8 months ago

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

May 14, 2024, 7:00 AM EDT - 8 months ago

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

May 13, 2024, 7:00 AM EDT - 8 months ago

ORLADEYO® (berotralstat) Approved in Mexico

May 9, 2024, 7:00 AM EDT - 9 months ago

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

May 6, 2024, 11:42 AM EDT - 9 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript

May 6, 2024, 7:00 AM EDT - 9 months ago

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 22, 2024, 7:00 AM EDT - 9 months ago

BioCryst to Report First Quarter 2024 Financial Results on May 6

Apr 17, 2024, 4:30 AM EDT - 9 months ago

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

Feb 26, 2024, 11:29 AM EST - 11 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 7:00 AM EST - 11 months ago

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

Feb 23, 2024, 7:00 AM EST - 11 months ago

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

Feb 19, 2024, 7:54 AM EST - 11 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Italy

Feb 12, 2024, 7:00 AM EST - 1 year ago

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

Feb 5, 2024, 7:00 AM EST - 1 year ago

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Jan 5, 2024, 4:01 PM EST - 1 year ago

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

Jan 3, 2024, 7:00 AM EST - 1 year ago

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 19, 2023, 7:00 AM EST - 1 year ago

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

Dec 14, 2023, 6:34 PM EST - 1 year ago

BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely

Nov 29, 2023, 7:00 AM EST - 1 year ago

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

Nov 21, 2023, 7:00 AM EST - 1 year ago

BioCryst Launches ORLADEYO® (berotralstat) in Spain

Nov 10, 2023, 7:00 AM EST - 1 year ago

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

Nov 3, 2023, 12:03 PM EDT - 1 year ago

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

Nov 3, 2023, 12:00 PM EDT - 1 year ago

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector®

Nov 2, 2023, 4:05 PM EDT - 1 year ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 7:00 AM EDT - 1 year ago

BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 27, 2023, 7:00 AM EDT - 1 year ago

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

Oct 26, 2023, 7:00 AM EDT - 1 year ago

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

Oct 20, 2023, 7:00 AM EDT - 1 year ago

BioCryst to Host R&D Day on November 3

Oct 19, 2023, 7:00 AM EDT - 1 year ago

BioCryst to Report Third Quarter 2023 Financial Results on November 2

Sep 18, 2023, 7:00 AM EDT - 1 year ago

INESSS Recommends Public Reimbursement for BioCryst's ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Aug 15, 2023, 1:00 AM EDT - 1 year ago

Harley, Spotify, and 8 Other Dead Money Stocks That Are Poised to Come Alive

SPOT BIIB BK HOG KWR LAZ SMG

Aug 3, 2023, 12:55 PM EDT - 1 year ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript